PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Lauds Sagent Pharmaceuticals for its Line of High-quality Heparin Preparations - Sagent Pharmaceuticals' heparin line's sophisticated PreventIV MeasuresSM Packaging and Labeling system helps prevent medication errors - Awards.Frost.com
Frost & Sullivan Lauds Sagent Pharmaceuticals for its Line of High-quality Heparin Preparations

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2011/10/19 - Sagent Pharmaceuticals' heparin line's sophisticated PreventIV MeasuresSM Packaging and Labeling system helps prevent medication errors - Awards.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the finished heparin market, Frost & Sullivan recognizes Sagent Pharmaceuticals, Inc. with the 2011 North American Frost & Sullivan Award for Product Quality Leadership. Sagent Pharmaceuticals' recently approved line of superior heparin injection preparations is available in a wide assortment of concentrations and package sizes, which are supplied in clearly labeled and color-differentiated packages to simplify use and help prevent medication errors. The availability of a variety of strengths and package sizes from a single supplier also helps to facilitate ordering, dispensing and administration.

Recently, the medical community was faced with a severe shortage of heparin due to the toxic contamination of heparin active pharmaceutical ingredients (APIs) and the resulting nationwide withdrawal of a large portion of the heparin supply. Sagent Pharmaceuticals helped alleviate this situation by locating an alternative supplier of safe ingredients to produce finished heparin preparations. These products were able to pass both the United States Pharmacopeia (USP) and the Food and Drug Administration's (FDA's) stringent new standards and eventually, the company launched its line of heparin injection products.

"Consumer confidence in the product's reliability is reflected in Sagent's rapid market uptake, leading to approximately 18.6 percent market share in just six months, and eventually, 25.4 percent for the first year on the market," says Frost & Sullivan Industry Analyst Debbie Toscano. "The true value of this product lies in the purity of the ingredients and user-friendly packaging, both of which Sagent delivers."

Sagent Pharmaceuticals' heparin injection product labeling was designed using the company's proprietary PreventIV MeasuresSM Packaging and Labeling, which is a user-centric approach to product packaging and labeling. Its unique features include easy-to-read product name, concentration and fill volume, and bold, color-differentiated labels, caps and cartons. Such detailed labeling clearly distinguishes each product and offers greater overall value for buyers, wholesalers, pharmacists, clinicians and patients.

"Since there are eleven unique total strengths of heparin sodium injection but only four different solution concentrations, the traditional labeling approach to this product makes it very easy for users to select the right concentration but the wrong total strength," notes Toscano. "Therefore, in addition to the use of a unique color for each total strength, Sagent has placed the vial fill volume information directly adjacent to the concentration information."

To further clarify the intended use of the product, Sagent has included a die cut warning strip on the vial labels and cartons, indicating that the product is not to be used as a Heparin Lock Flush, which is a common and very serious error that has led to many fatalities. Sagent Pharmaceuticals offers labeling solutions not only for the vials but the cartons as well. Unlike competitors' shrink-wrapped trays, Sagent's full-color cartons are clearly labeled on all four sides and top, as well as bar coded on two panels, enabling easy identification by purchasers and pharmacy technicians.

Heparin is frequently used in critical care as well as routine procedures such as dialysis. The required concentration and volume depends on the particular application and the dose may have to be frequently adjusted to suit the patient's body weight or individual coagulation status. Hence, a product, which is available in a variety of package sizes and concentrations under a single brand label, offers greater ease of use and eliminates the requirement to switch brands based on need.

Each year, Frost & Sullivan presents this award to a company that has developed high-quality products with innovative features and functionalities. The winner of this award has developed and launched a product that enhances customer value and finds immediate acceptance in the market. Sagent's Heparin Sodium Injection, USP with PreventIV MeasuresSM Packaging and Labeling demonstrates this leadership.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Lauds Sagent Pharmaceuticals for its Line of High-quality Heparin Preparations

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Mireya Espinoza 
210-247-3870 mireya.espinoza[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)